Asterisks preceding the title refer to studies in humans.

189 Frequency of Fish Tumors Found in a Polluted Watershed as Compared to Nonpolluted Canadian Waters.

199 Delayed Cutaneous Hypersensitivity to Cell-free Tumor Antigens.
E. Carmack Holmes, Ralph A. Reisfeld, and Donald L. Morton.

203 Studies on the Mechanism of Corticosteroid-induced Lymphocytolysis.

Ralph E. Durand and Robert M. Sutherland.

220 Hormonal Effects on Thymidine Kinase and Thymidylate Kinase Activity of Estrogen-dependent Tumors in the Rat.

226 * Clinical Pharmacology of Cyclophosphamide.
Charles M. Bagley, Jr., Frieda W. Bostick, and Vincent T. DeVita, Jr.

234 Ultrastructural Effects of 5-Bromodeoxyuridine and 5-Fluorouracil in Drosophila.
T. M. Rizki, Rose M. Rizki, and Mary Ann Lommen.

249 * Activities and Isoenzyme Patterns of Some Enzymes of Glucose Metabolism in Human Primary Malignant Hepatoma.

256 The Effects of Immunization of L-Asparaginase on Antitumor and Enzymatic Activity.

262 The Carcinogenic Potential of Aflatoxin or Its Metabolites in Rats from Dams Fed Aflatoxin Pre- and Postpartum.

269 Ultrastructural, Histological, and Biochemical Alterations Produced by 12-O-Tetradecanoylphorbol-13-acetate on Mouse Epidermis and Their Relevance to Skin Tumor Promotion.
Alberto N. Raick.

287 Chondral Dysplasia Induced by Zirconium and Hafnium.
Walter B. Shelley.

293 Comparative Studies of Subcutaneous and Intradermal Leukemic Tumors in Guinea Pigs.

302 Mutagenic Properties of Benzo(a)pyrene and Its Methylated Derivatives in Relation to the Molecular Mechanisms of Hydrocarbon Carcinogenesis.
O. G. Fahmy and Myrtle J. Fahmy.

310 Modified Nucleosides with Antineoplastic Activity as Inhibitors of an Enzyme Containing Adenosine within Its Coenzyme.
George L. Trisch.

313 * Carcinoembryonic Antigen and Blood Group Substances.
D. Alastair R. Simmons and Peter Perlmann.

323 Inhibition of Transfer and Ribosomal RNA Methylases by Polyinosinate.
Ming C. Liao, John B. Hunt, Don W. Smith, and Robert B. Hurlbert.

332 Transplantability and Biological Behavior of Mouse Liver Tumors Induced by Ethynitrosourea.
A. P. Kyriazis and S. D. Vesselinovitch.

339 Role of Hormonal Environment, Partial Hepatectomy, and Dose of Ethynitrosourea in Renal Carcinogenesis.

342 Radioiron Incorporation by a Transplantable Lymphoid Tumor.
Francis W. Chandler, Jr., and Oscar J. Fletcher, Jr.

351 In Vitro Neoplastic Transformation of Hamster Embryonic Skin and Subcutaneous Tissue Cells with Small-Plaque and Large-Plaque Variants of an Avian Adenovirus (Chicken Embryo Lethal Orphan).
Richard G. Pendola and Vance J. Yates.

356 Cyclic Adenosine 3',5'-Monophosphate Phosphodiesterase Activity in Normal, Differentiating, Regenerating, and Neoplastic Liver.

Early Effects of Glucocorticoid Treatment on Amino Acid Metabolism in Lymphosarcoma P1798. J. Stevens, Y-W. Stevens, and V. P. Hollander.

Reversible and Irreversible Effects of Tissue Culture on Enzyme Patterns of Spontaneous Mouse Tumors and Mouse and Human Embryo Tissues. Patricia D. Wilson.

Folate Deficiency and Formiminoglutamic Acid Excretion during Chronic Diethylnitrosamine Administration to Rats. Lionel A. Poirier and V. Michael Whitehead.


Dihydroorotate Dehydrogenase in Liver and Morris Hepatomas. Martin J. Sweeney and David H. Hoffman.


Enhancement of Adenovirus Transformation by Treatment of Hamster Cells with Ultraviolet Irradiation, DNA Base Analogs, and Dibenz(a,h)anthracene. Bruce C. Casto.

Alterations of Cell-mediated Immunity in the Mouse following Administration of 4-Nitroquinoline 1-Oxide. H. C. Outzen and R. T. Prehn.


Books Received.

Announcements.

COVER LEGEND

The 1972 Albert Lasker Medical Research Awards were extended to 17 individuals, for 7 categories of accomplishment in clinical cancer chemotherapy: (1) Use of drugs in cures of gestational choriocarcinoma (Li and Hertz). (2) Use of drugs in long-term disease-free survivors with Burkitt's tumor (Burkitt, Burchenal, Ngu, and Ziegler). (3) Use of topical chemotherapy and enhancement of host response for cures in skin cancers (Klein). (4) Use of combination drug therapy resulting in prolonged survival, in acute lymphatic leukemia (Frei, Freireich, Holland, and Pinkel). (5) Use of combination drug therapy, resulting in prolonged survival, in Hodgkin's disease (Frei, Carbone, and DeVita). (6) Treatment of mycosis fungoides, with topical chemotherapy and enhancement of host response (Van Scott). (7) Supportive measures in treatment of toxicity, infection, and hemorrhage, due to side effects of drugs (Djerassi and Freireich).

A special Award was presented to Dr. C. Gordon Zubrod of the National Cancer Institute, for his leadership in the National Cancer Institute program of chemotherapy.

The group picture of the awards ceremonies, held on November 16, 1972, in New York, shows: Left to right, seated in first row: Dr. Isaac Djerassi, Director of Research Hematology at Mercy Catholic Medical Center (Fitzgerald Division), Darby, Pa.; Dr. Edmund Klein, Chief of Department of Dermatology at Roswell Park Memorial Institute, Buffalo, N. Y.; Mrs. Albert D. Lasker, President of the Albert and Mary Lasker Foundation; Dr. Sidney Farber, Chairman of the Awards Jury; also President and Director of the Children's Cancer Research Foundation, Boston, Mass.; Mrs. Alice Fordyce, Vice President of the Albert and Mary Lasker Foundation; Special Award Winner, Dr. C. Gordon Zubrod, Director of the Division of Cancer Treatment at the National Cancer Institute, Bethesda, Md.; Dr. Roy Hertz, Professor of Obstetrics and Gynecology and Director of Clinical Research at New York Medical College, Valhalla, N. Y. Seated in second row: Dr. Min Chiu Li, Director of Medical Research at Nassau Hospital, Mineola, N. Y.; Dr. Eugene J. Van Scott, Professor of Dermatology at Temple University, Philadelphia, Pa.; Dr. Paul P. Carbone, Associate Scientific Director for Medical Oncology at the National Cancer Institute and National Institutes of Health, Bethesda, Md.; Dr. John L. Ziegler, Director at Uganda Cancer Institute, Kampala, Uganda, Africa; Dr. Joseph H. Burchenal, Director of Clinical Investigation at Memorial Hospital for Cancer and Allied Diseases, New York, N. Y.; Mr. Denis Burkitt, Surgeon at Medical Research Council, London, England; Dr. Emil J. Freireich, Professor of Medicine and Chief of Research Hematology at the University of Texas, Houston, Texas. Standing: Dr. Emil Frei, III, Physician-in-Chief at Children's Cancer Research Foundation, Boston, Mass.; Dr. Vincent T. DeVita, Jr., Chief of Medicine Branch at National Cancer Institute, Bethesda, Md.; Dr. V. Anomah Ngu, Professor of Surgery at Centre of Health Sciences, Yaounde, United Republic of Cameroun, Africa; Dr. Donald Pinkel, Medical Director at St. Jude Children's Research Hospital, Memphis, Tenn. Absent was Dr. James F. Holland, Director, Cancer Clinical Research Center at Roswell Park Memorial Institute, Buffalo, N. Y.

Updated version | Access the most recent version of this article at: [Updated Version](http://cancerres.aacrjournals.org/content/33/2.citation)

**E-mail alerts** | Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions** | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions** | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.